A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata

November 2018 in “ Archives of dermatological research ”

Daniela Mikhaylov, Ana B. Pavel, Christopher J. Yao, Grace W. Kimmel, John K Nia, Peter W. Hashim, Anjali S. Vekaria, Mark Taliercio, Giselle Singer, Rachel Karalekas, Danielle Baum, Yasaman Mansouri, Mark Lebwohl, Emma Guttman‐Yassky

apremilast alopecia areata Severity of Alopecia Tool SALT score PDE4 pathway nausea

Studysummary Apremilast was not effective in treating moderate-to-severe alopecia areata.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

In a pilot study from 2018, 30 patients with moderate-to-severe alopecia areata were randomized to receive either apremilast (20 patients) or a placebo (10 patients) over 24 weeks to test the drug's safety and efficacy. The primary goal was a 50% reduction in Severity of Alopecia Tool (SALT) score at 24 weeks. The results showed that apremilast was not significantly effective, with only 1 of 12 subjects in the apremilast group and 1 of 8 in the placebo group meeting the primary endpoint. The mean improvement in SALT score was not significantly different between the two groups. The study concluded that apremilast did not demonstrate efficacy in treating moderate-to-severe alopecia areata and suggested that the PDE4 pathway might not be significantly involved in the condition's pathogenesis. Adverse events were similar in both groups, with nausea being the most common in the apremilast group. The authors recommended larger studies to confirm these findings and suggested that PDE4 inhibition might still be beneficial for patients with milder forms of the condition.

View this study on doi.org →

Discuss this study in the Community →

Research cited in this study

25 / 25 results

research An Investigation of Vitamin D Status in Alopecia Areata

37 citations , June 2018 in “Clinical and Experimental Medicine”

This study found that patients with alopecia areata had significant systemic inflammation and vitamin D deficiency, with both conditions more pronounced as disease severity increased.

research Lack of Efficacy of Apremilast in 9 Patients with Severe Alopecia Areata

23 citations , September 2017 in “Journal of the American Academy of Dermatology”

This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.

research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm

77 citations , June 2017 in “Advances in Therapy”

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

research The Changing Landscape of Alopecia Areata: The Translational Landscape

16 citations , June 2017 in “Advances in Therapy”

This review summarizes recent research on alopecia areata, highlighting advances in targeted therapies due to improved understanding of its immunopathogenesis, though it reports no new clinical results.

research Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata

83 citations , June 2017 in “Journal of the American Academy of Dermatology”

This study observed that most pediatric patients with alopecia areata experienced some hair regrowth after treatment with topical JAK inhibitors, and the formulations were generally well-tolerated with mild lab abnormalities in some cases.

research Reversal of Alopecia Universalis by Tofacitinib: A Case Report

14 citations , November 2016 in “Annals of Internal Medicine”

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , November 2016 in “Journal of The American Academy of Dermatology”

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

196 citations , September 2016 in “JCI insight”

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

research A Novel Therapeutic Paradigm for Patients with Extensive Alopecia Areata

30 citations , May 2016 in “Expert Opinion on Biological Therapy”

This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.

research Extensive Alopecia Areata Is Reversed by IL-12/IL-23p40 Cytokine Antagonism

68 citations , November 2015 in “The Journal of Allergy and Clinical Immunology”

In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.

research Current Treatments for Alopecia Areata

21 citations , November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings”

This review discusses recent therapeutic approaches for alopecia areata, including the use of Janus kinase inhibitors and interleukin-2, and reports no new clinical results.

research Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing

176 citations , August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.

research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

184 citations , February 2015 in “EBioMedicine”

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

research The PDE4 Inhibitor, Apremilast, Suppresses Experimentally Induced Alopecia Areata in Human Skin In Vivo

52 citations , December 2014 in “Journal of Dermatological Science”

Apremilast may help treat hair loss in alopecia areata.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

research Clinical Efficacy of Diphenylcyclopropenone in Alopecia Areata: Retrospective Data Analysis of 50 Patients

14 citations , August 2014 in “Journal of the American Academy of Dermatology”

This study found that topical diphenylcyclopropenone is an effective treatment for extensive alopecia areata, with significant hair regrowth reported in most patients, though effectiveness varied with disease characteristics.

research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

185 citations , June 2014 in “Journal of Investigative Dermatology”

This case report describes complete hair regrowth in a patient with alopecia universalis and improved psoriasis after treatment with the oral Janus kinase inhibitor, tofacitinib.

research The Effect of Oral Cyclosporine in the Treatment of Severe Alopecia Areata

33 citations , October 2013 in “Cutaneous and ocular toxicology”

This article discusses the autoimmune pathogenesis of alopecia areata and reviews the use of immunosuppressive therapies in its treatment, but it does not provide new clinical results.

Combination Therapy with Cyclosporine and Psoralen Plus Ultraviolet A in Patients with Severe Alopecia Areata: A Retrospective Study with a Self-Controlled Design

research Combination Therapy with Cyclosporine and Psoralen Plus Ultraviolet A in Patients with Severe Alopecia Areata: A Retrospective Study with a Self-Controlled Design

21 citations , January 2013 in “Annals of dermatology/Annals of Dermatology”

In this study, combination therapy with cyclosporine and PUVA for severe alopecia areata resulted in a majority of patients showing only fair to poor responses, though some improvements were noted.

research Systemic Treatment for Alopecia Areata

16 citations , May 2011 in “Dermatologic therapy”

This article reviews side effects and relapse rates of various systemic treatments for severe alopecia areata, reporting no new clinical findings.

research Alopecia Areata Update

244 citations , January 2010 in “Journal of the American Academy of Dermatology”

This review discusses treatment options for alopecia areata and suggests tailored treatment plans, noting the challenges posed by spontaneous remission and limited high-quality clinical trials.

research Interventions for Alopecia Areata

164 citations , April 2008 in “Cochrane library”

This review of interventions for alopecia areata found no significant treatment benefits for hair growth compared to placebo, indicating a need for larger, well-conducted studies.

research A Comparison of the Efficacy, Relapse Rate, and Side Effects Among Three Modalities of Systemic Corticosteroid Therapy for Alopecia Areata

97 citations , January 2006 in “Dermatology”

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.

research Alopecia Areata: A Tissue-Specific Autoimmune Disease of the Hair Follicle

185 citations , August 2005 in “Autoimmunity Reviews”

This review discusses alopecia areata as a model for studying tissue-directed autoimmune diseases and reports no new clinical findings.

research Guidelines for the Management of Alopecia Areata

182 citations , October 2003 in “British Journal of Dermatology”

These guidelines for alopecia areata management, prepared by the British Association of Dermatologists, provide evidence-based treatment recommendations and insights into the condition's epidemiology, diagnosis, and investigation.